View Financial HealthLaekna 配当と自社株買い配当金 基準チェック /06Laekna配当金を支払った記録がありません。主要情報n/a配当利回り-24.3%バイバック利回り総株主利回り-24.3%将来の配当利回り0%配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新お知らせ • Jul 11Laekna, Inc. (SEHK:2105) commences an Equity Buyback Plan for 44,933,135 shares, representing 10% of its issued share capital, under the authorization approved on June 5, 2026.Laekna, Inc. (SEHK:2105) commences share repurchases on July 9, 2026, under the program mandated by the shareholders in the Annual General Meeting held on June 5, 2026. As per the mandate, the company is authorized to repurchase up to 44,933,135 units, representing 10% of its issued share capital. The purpose for the buyback is to enhance the net asset value per share and/or earnings per share. The repurchases will be made out of the funds legally available for such purpose in accordance with trust deed and applicable laws of, and regulations in Hong Kong. The shares repurchased will be cancelled. The authority shall expire at the earliest of the next Annual General Meeting, the date on which the next Annual General Meeting is required to be held or the date on which the authority is carried out to the full extent, unless varied or revoked in a General Meeting. As of May 14, 2026, the company had 449,331,350 shares in issue. On July 2, 2026, the company announces a Share Repurchase Program. Under the program, the company will repurchase up to HKD 56 million worth of its shares. The share share repurchase will be funded by the Company’s existing available cash resources.すべての更新を表示Recent updatesお知らせ • Aug 19Laekna, Inc. Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2026Laekna, Inc. provided consolidated earnings guidance for the six months ended 30 June 2026. for the six months, the Group is expected to record revenue in the range of approximately RMB 145 million to RMB 155 million for the Reporting Period, as compared to nil for the six months ended 30 June 2025 and a consolidated net loss of no more than RMB 5 million for the Reporting Period as compared to a consolidated net loss of approximately RMB 130 million for the Corresponding Period, representing a significant decrease in loss of approximately 96% year-on-year. The anticipated increase in revenue and significant decrease in consolidated net loss during the Reporting Period were mainly attributable to the revenue recognized under the exclusive license agreements which the Group entered into with Vasque Bio, Inc. with respect to LAE118, and Qilu Pharmaceutical Company Limited with respect to LAE002 (afuresertib).お知らせ • Aug 12Laekna, Inc. New Drug Application for LAE002 (Afuresertib) Is Accepted by China's National Medical Products AdministrationLaekna, Inc. announced that the New Drug Application (NDA) for LAE002 (afuresertib) has been accepted by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer (LA/mBC) with PIK3CA/AKT1/PTEN alterations, following recurrence or progression on or after endocrine therapy(-ies) (with or without a CDK4/6 inhibitor). The NDA is supported by positive results from the Phase III Clinical Trial (AFFIRM-205) conducted in the aforementioned patient population. This pivotal study successfully met its primary endpoint of progression-free survival (PFS), demonstrating a highly statistically significant and clinically meaningful improvement over the control arm. LAE002 (afuresertib) also showed a favorable safety and tolerability profile. The detailed study results will be presented at an upcoming international scientific conference. Laekna is collaborating with its strategic partner, Qilu Pharmaceutical, to expedite the regulatory approval and commercialization of LAE002 (afuresertib) in China. As a potential Class I novel drug for breast cancer and the first domestically developed AKT inhibitor in China, the clinical results of LAE002 (afuresertib) have demonstrated a best-in-class efficacy and safety profile. Beyond breast cancer, the clinical development of LAE002 (afuresertib) for prostate cancer is also advancing rapidly. Laekna is actively pursuing strategic partnerships in ex-China regions to accelerate development and commercialization of LAE002 (afuresertib) in international markets. LAE002 (afuresertib) marks the first breakthrough of Laekna's innovative pipeline, as well as a significant milestone in its transition to the commercial stage. Laekna and Qilu Pharmaceutical entered into an exclusive licensing agreement for the China region in November 2025. Under the License Agreement, Laekna is eligible to receive up to RMB 2,045 million in total in upfront and milestone payments and is also entitled to receive tiered royalties on future net sales of LAE002 (afuresertib) in the licensed territory, at percentages ranging from the low teens to the low twenties. Laekna plans to pursue strategic partnerships in ex-China regions to accelerate development and commercialization of LAE002 (afuresertib) in international markets. Capivasertib (Truqap) was the first approved AKT inhibitor from AstraZeneca, which was approved by the U.S. FDA for HR+/HER2- breast cancer in November 2023. In June 2026, the U.S. FDA further approved capivasertib (Truqap) in combination with abiraterone and prednisone for the treatment of PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC). This approval significantly broadens the therapeutic scope of AKT inhibition and highlights its potential to address unmet needs across multiple tumor types. LAE002 (afuresertib) is a potent AKT inhibitor internally developed by Laekna that inhibits all three AKT isoforms (AKT1, AKT2 and AKT3). It is one of the two most advanced AKT inhibitors globally in development for breast and prostate cancer. The Phase III clinical trial (AFFIRM-205), a multi-center, randomized, double-blind, placebo-controlled pivotal study, has met its primary endpoint of progression-free survival. It showed statistically significant and clinically meaningful benefits to patients with HR+/HER2- breast cancer and demonstrated a best-in-class efficacy and safety profile. Breast cancer has become the leading cause of death for women globally, with approximately 2,430,000 new cases diagnosed each year and around 694,000 lives lost to the disease. In China, breast cancer ranks the second most common cancer among women, with approximately 70% of the patients found to be HR+/HER2-. Collectively, genetic alterations in PIK3CA, AKT1 and PTEN affect approximately 50% of patients with breast cancer. Although most patients with this subtype of breast cancer can initially benefit from first/second-line treatment by endocrine therapy + CDK4/6 inhibitors and/or chemotherapy, they may gradually develop drug resistance and result in treatment failure. Novel therapeutic options are urgently needed for patients after drug resistance. As an innovative therapy for drug-resistant patients with this subtype of breast cancer, AKT inhibitors offer new hope for them and their families.お知らせ • Aug 08Laekna, Inc. to Report First Half, 2026 Results on Aug 25, 2026Laekna, Inc. announced that they will report first half, 2026 results on Aug 25, 2026お知らせ • Jul 11Laekna, Inc. (SEHK:2105) commences an Equity Buyback Plan for 44,933,135 shares, representing 10% of its issued share capital, under the authorization approved on June 5, 2026.Laekna, Inc. (SEHK:2105) commences share repurchases on July 9, 2026, under the program mandated by the shareholders in the Annual General Meeting held on June 5, 2026. As per the mandate, the company is authorized to repurchase up to 44,933,135 units, representing 10% of its issued share capital. The purpose for the buyback is to enhance the net asset value per share and/or earnings per share. The repurchases will be made out of the funds legally available for such purpose in accordance with trust deed and applicable laws of, and regulations in Hong Kong. The shares repurchased will be cancelled. The authority shall expire at the earliest of the next Annual General Meeting, the date on which the next Annual General Meeting is required to be held or the date on which the authority is carried out to the full extent, unless varied or revoked in a General Meeting. As of May 14, 2026, the company had 449,331,350 shares in issue. On July 2, 2026, the company announces a Share Repurchase Program. Under the program, the company will repurchase up to HKD 56 million worth of its shares. The share share repurchase will be funded by the Company’s existing available cash resources.お知らせ • May 15Laekna, Inc., Annual General Meeting, Jun 05, 2026Laekna, Inc., Annual General Meeting, Jun 05, 2026, at 09:00 China Standard Time. Location: 5f, 987 cailun road, pudong, shanghai, china, Hong Kongお知らせ • Mar 06Laekna, Inc. to Report Fiscal Year 2025 Results on Mar 18, 2026Laekna, Inc. announced that they will report fiscal year 2025 results at 4:00 PM, China Standard Time on Mar 18, 2026お知らせ • Jan 14Laekna, Inc. Announces That the U.S. Food and Drug Administration Has Accepted Its Investigational New Drug Application for LAE118The board of directors of Laekna, Inc. announced that the U.S. Food and Drug Administration has accepted its Investigational New Drug application for LAE118, a novel PI3K a pan-mutant selective inhibitor for the treatment of patients with PIK3CA-mutant solid tumors. The Company will work closely with the regulatory authorities to complete the application. Building on its proven track record in successfully developing and out-licensing LAE002 (afuresertib), the Company aims to bring this precision therapy to cancer patients who are in need of novel treatment options.お知らせ • Jan 02Laekna, Inc. Commences Study Recruitment in Phase I Single Ascending Dose Study of LAE103The board of directors of Laekna, Inc. announced that the Group has commenced study recruitment in phase I single ascending dose study of LAE103, an internally discovered monoclonal antibody against ActRIIB, in Australia. As of the date of this announcement, first subject has been dosed. The SAD Study is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of LAE103, administered subcutaneously, in healthy overweight or obese participants. The Group targets to read out the topline data of this SAD study in the third quarter of 2026. The Group targets to bring this precision therapy to cardiovascular and metabolic diseases with high unmet medical needs, such as obesity, sarcopenia and heart failure.お知らせ • Sep 18Laekna, Inc. has completed a Follow-on Equity Offering in the amount of HKD 586.8 million.Laekna, Inc. has completed a Follow-on Equity Offering in the amount of HKD 586.8 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 36,000,000 Price\Range: HKD 16.3 Discount Per Security: HKD 0.26 Transaction Features: Subsequent Direct Listingお知らせ • Sep 11Laekna, Inc. has filed a Follow-on Equity Offering in the amount of HKD 586.8 million.Laekna, Inc. has filed a Follow-on Equity Offering in the amount of HKD 586.8 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 36,000,000 Price\Range: HKD 16.3 Discount Per Security: HKD 0.26 Transaction Features: Subsequent Direct Listingお知らせ • Jul 29Laekna, Inc. to Report First Half, 2025 Results on Aug 13, 2025Laekna, Inc. announced that they will report first half, 2025 results on Aug 13, 2025お知らせ • Jun 30Laekna, Inc. Submits Investigational New Drug Application to the U.S. Food and Drug AdministrationThe board of directors of Laekna, Inc. announced that the Group has submitted an Investigational New Drug application to the U.S. Food and Drug Administration for LAE103, an internally discovered monoclonal antibody against ActRIIB for the treatment of patients with sarcopenic obesity and muscle related disease. The Company will work closely with the regulatory authorities to complete the application and targets to bring this precision therapy to metabolic patients who are in need of novel treatment options. The Group plans to separately evaluate the efficacy and safety of monoclonal antibodies targeting at ActRIIA and ActRIIB in humans.お知らせ • Jun 24Laekna Presents Clinical and Pre-clinical Studies Results of LAE102, LAE103 and LAE123Laekna announced that the results of: i) the phase I SAD study of LAE102 (an ActRIIA-selective antibody) for the treatment of obesity; and ii) the pre-clinical study of LAE102, LAE103 (an ActRIIB-selective antibody) and LAE123 (an ActRIIA/IIB dual antagonistic monoclonal antibody) as therapeutics for muscle growth and fat reduction were presented at the 85th scientific sessions of the American Diabetes Association (ADA). ADA is one of the global leading conferences dedicated to diabetes research, care, and innovation and has taken place in Chicago, USA, from June 20 to 23 this year. Professor Xuening LI, Zhongshan Hospital affiliated to Fudan University,Principal Investigator of the Phase I Clinical Trial of LAE102 in China. At the ADA Scientific Sessions, Laekna showcased LAE102, LAE102, LAE 103, and LAE123 - an innovative portfolio targeting the ActRII pathway - highlighting team's extensive expertise and leadership in this field. Highlights: A total of 40 participants were enrolled in Part A (IV) and 24 participants in Part B (SC). All participants completed the study as designed. The mean age was 29.0 years and 31.2 years, with the mean BMI 23.32 kg/m2 and 23.08 kg/m2 in Part A and Part B, respectively.お知らせ • Jun 23Laekna, Inc. Announces Results of Phase I Sad Study of Lae102Laekna, Inc. announced that the results of (i) phase I SAD study of LAE102 (an ActRIIA-selective antibody) for the treatment of obesity; and (ii) the pre-clinical study of LAE102, LAE103 (an ActRIIB-selective antibody) and LAE123 (an ActRIIA/IIB dual antagonistic monoclonal antibody) as therapeutics for muscle growth and fat reduction were presented at the 85th scientific sessions of the American Diabetes Association (ADA). Presentations details are as follows: Poster No.1. Abstract Number: 2205-LB, Title: First-in-Human Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LAE102 in Healthy volunteers, Time: Sunday, June 22, 2025, 12:30 p.m.-13:30 p.m. CST, Location: Poster Hall (Hall F1) McCormick Place Convention Center, Chicago, Illinois, the USA. Highlights: A total of 40 participants were enrolled in Part A (IV) and 24 participants in Part B (SC). All participants completed the study as designed. The mean age was 29.0 years and 31.2 years, with the mean BMI 23.32 kg/m2 and 23.08 kg/m2 in Part A and Part B, respectively. Baseline demographic and clinical characteristics were generally balanced across the intravenous (IV) and subcutaneous (SC) cohorts of the study. Overall, LAE102 was well tolerated following a single IV or SC dose. No serious adverse events or treatment emergent adverse events (TEAEs) leading to discontinuation of treatment were reported. The majority of the TEAEs were mild laboratory test abnormalities, which were asymptomatic and did not require medical intervention. There was no reported case of diarrhea. Activin A was significantly increased in 24 hours following a single intravenous or subcutaneous dose of LAE102. The duration of Activin A elevation was dose-dependent. The high-dose groups (8 mg/kg IV group, 16 mg/kg IV group, and 8 mg/kg SC group) maintained 2-to-3-fold increases above the baseline level through 28 days post-administration, indicating prolonged pathway blocking. In addition, they also inhibit activin E and GDF3, which promote lipid accumulation of adipose tissue. In mouse models, LAE102 alone significantly induced muscle growth and reduced fat mass, while LAE103 had less effect. Notably, a synergistic effect on muscle increase and fat loss was observed when combining LAE102 with LAE103, achieving the maximal effect comparable to the ActRIIA-IIB dual-specific antibody LAE123. This positions LAE102 as a promising drug candidate for achieving quality weight control.お知らせ • May 13Laekna, Inc., Annual General Meeting, Jun 03, 2025Laekna, Inc., Annual General Meeting, Jun 03, 2025, at 09:00 China Standard Time. Location: 5f, 987 cailun road, pudong, shanghai Chinaお知らせ • Mar 26Laekna, Inc. Commences Study Recruitment in Phase I Multiple Ascending Dose Study of Lae102 for the Treatment of ObityThe board of directors of Laekna, Inc. announced that the Group has commenced study recruitment in phase I multiple ascending dose study of LAE102 in China for the treatment of obesity. As of the date of this announcement, the first visit for the first subject has been completed. The MAD Study is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of LAE102, administered subcutaneously, in 60 overweight/obese subjects. The Group aims to bring this precision therapy to overweight and obese patients who are in need of novel treatment options for achieving quality weight control.お知らせ • Mar 10Laekna, Inc. to Report Fiscal Year 2024 Results on Mar 24, 2025Laekna, Inc. announced that they will report fiscal year 2024 results on Mar 24, 2025お知らせ • Jan 13Laekna, Inc. Announces Completion of A Successful Phase I Single Ascending Dose Study of Lae102 for the Treatment of ObesityThe board of directors of Laekna, Inc. announced that the Group has successfully completed the phase I single ascending dose study of LAE102 for the treatment of obesity. The SAD Study enrolled a total of 64 healthy subjects with an average BMI of 23.2+-2.2 kg/m2, including 5 intravenous cohorts and 3 subcutaneous cohorts. The positive outcomes of the SAD Study results have established a solid foundation for the coming phase I multiple ascending dose study in China as well as the phase I clinical study in collaboration with Eli Lilly & Company in the U.S. The SAD Study data of LAE102 analyzed to date demonstrated an encouraging safety and tolerability profile, with no serious adverse events and no discontinuations due to adverse events. All treatment emergent adverse events reported to date were very well tolerated, with the majority of them being reported as mild (grade 1) lab test abnormality without any clinical symptoms or signs. There is no reported case of diarrhea. Obvious target engagements and expected pharmacodynamic biomarker changes have been observed. Single doses of LAE102 resulted in significant and sustained increasing in activin A level, indicating a robust target engagement. The duration of target engagement correlated to the dose level. The detailed study results will be presented in a scientific conference as soon as possible. The positive SAD Study results support continuing the investigation of LAE102 for thetreatment of obesity. The Group plans to initiate the MAD Study in the first quarter of 2025 and to work closely with Lilly to commence the phase I clinical study in U.S. as soon as possible. The MAD Study is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of LAE102, administered subcutaneously, in 60 overweight/obese subjects. The Group aims to bring this precision therapy to overweight and obese patients who are in need of novel treatment options for achieving quality weight control.決済の安定と成長配当データの取得安定した配当: LAEK.Fの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: LAEK.Fの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Laekna 配当利回り対市場LAEK.F 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (LAEK.F)n/a市場下位25% (US)1.3%市場トップ25% (US)4.0%業界平均 (Biotechs)1.8%アナリスト予想 (LAEK.F) (最長3年)0%注目すべき配当: LAEK.Fは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: LAEK.Fは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: LAEK.Fの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: LAEK.Fが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/21 11:10終値2026/07/31 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Laekna, Inc. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Bo LiBofA Global Researchnull nullChina International Capital Corporation LimitedYaxin LiuChina International Capital Corporation Limited1 その他のアナリストを表示
お知らせ • Jul 11Laekna, Inc. (SEHK:2105) commences an Equity Buyback Plan for 44,933,135 shares, representing 10% of its issued share capital, under the authorization approved on June 5, 2026.Laekna, Inc. (SEHK:2105) commences share repurchases on July 9, 2026, under the program mandated by the shareholders in the Annual General Meeting held on June 5, 2026. As per the mandate, the company is authorized to repurchase up to 44,933,135 units, representing 10% of its issued share capital. The purpose for the buyback is to enhance the net asset value per share and/or earnings per share. The repurchases will be made out of the funds legally available for such purpose in accordance with trust deed and applicable laws of, and regulations in Hong Kong. The shares repurchased will be cancelled. The authority shall expire at the earliest of the next Annual General Meeting, the date on which the next Annual General Meeting is required to be held or the date on which the authority is carried out to the full extent, unless varied or revoked in a General Meeting. As of May 14, 2026, the company had 449,331,350 shares in issue. On July 2, 2026, the company announces a Share Repurchase Program. Under the program, the company will repurchase up to HKD 56 million worth of its shares. The share share repurchase will be funded by the Company’s existing available cash resources.
お知らせ • Aug 19Laekna, Inc. Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2026Laekna, Inc. provided consolidated earnings guidance for the six months ended 30 June 2026. for the six months, the Group is expected to record revenue in the range of approximately RMB 145 million to RMB 155 million for the Reporting Period, as compared to nil for the six months ended 30 June 2025 and a consolidated net loss of no more than RMB 5 million for the Reporting Period as compared to a consolidated net loss of approximately RMB 130 million for the Corresponding Period, representing a significant decrease in loss of approximately 96% year-on-year. The anticipated increase in revenue and significant decrease in consolidated net loss during the Reporting Period were mainly attributable to the revenue recognized under the exclusive license agreements which the Group entered into with Vasque Bio, Inc. with respect to LAE118, and Qilu Pharmaceutical Company Limited with respect to LAE002 (afuresertib).
お知らせ • Aug 12Laekna, Inc. New Drug Application for LAE002 (Afuresertib) Is Accepted by China's National Medical Products AdministrationLaekna, Inc. announced that the New Drug Application (NDA) for LAE002 (afuresertib) has been accepted by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer (LA/mBC) with PIK3CA/AKT1/PTEN alterations, following recurrence or progression on or after endocrine therapy(-ies) (with or without a CDK4/6 inhibitor). The NDA is supported by positive results from the Phase III Clinical Trial (AFFIRM-205) conducted in the aforementioned patient population. This pivotal study successfully met its primary endpoint of progression-free survival (PFS), demonstrating a highly statistically significant and clinically meaningful improvement over the control arm. LAE002 (afuresertib) also showed a favorable safety and tolerability profile. The detailed study results will be presented at an upcoming international scientific conference. Laekna is collaborating with its strategic partner, Qilu Pharmaceutical, to expedite the regulatory approval and commercialization of LAE002 (afuresertib) in China. As a potential Class I novel drug for breast cancer and the first domestically developed AKT inhibitor in China, the clinical results of LAE002 (afuresertib) have demonstrated a best-in-class efficacy and safety profile. Beyond breast cancer, the clinical development of LAE002 (afuresertib) for prostate cancer is also advancing rapidly. Laekna is actively pursuing strategic partnerships in ex-China regions to accelerate development and commercialization of LAE002 (afuresertib) in international markets. LAE002 (afuresertib) marks the first breakthrough of Laekna's innovative pipeline, as well as a significant milestone in its transition to the commercial stage. Laekna and Qilu Pharmaceutical entered into an exclusive licensing agreement for the China region in November 2025. Under the License Agreement, Laekna is eligible to receive up to RMB 2,045 million in total in upfront and milestone payments and is also entitled to receive tiered royalties on future net sales of LAE002 (afuresertib) in the licensed territory, at percentages ranging from the low teens to the low twenties. Laekna plans to pursue strategic partnerships in ex-China regions to accelerate development and commercialization of LAE002 (afuresertib) in international markets. Capivasertib (Truqap) was the first approved AKT inhibitor from AstraZeneca, which was approved by the U.S. FDA for HR+/HER2- breast cancer in November 2023. In June 2026, the U.S. FDA further approved capivasertib (Truqap) in combination with abiraterone and prednisone for the treatment of PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC). This approval significantly broadens the therapeutic scope of AKT inhibition and highlights its potential to address unmet needs across multiple tumor types. LAE002 (afuresertib) is a potent AKT inhibitor internally developed by Laekna that inhibits all three AKT isoforms (AKT1, AKT2 and AKT3). It is one of the two most advanced AKT inhibitors globally in development for breast and prostate cancer. The Phase III clinical trial (AFFIRM-205), a multi-center, randomized, double-blind, placebo-controlled pivotal study, has met its primary endpoint of progression-free survival. It showed statistically significant and clinically meaningful benefits to patients with HR+/HER2- breast cancer and demonstrated a best-in-class efficacy and safety profile. Breast cancer has become the leading cause of death for women globally, with approximately 2,430,000 new cases diagnosed each year and around 694,000 lives lost to the disease. In China, breast cancer ranks the second most common cancer among women, with approximately 70% of the patients found to be HR+/HER2-. Collectively, genetic alterations in PIK3CA, AKT1 and PTEN affect approximately 50% of patients with breast cancer. Although most patients with this subtype of breast cancer can initially benefit from first/second-line treatment by endocrine therapy + CDK4/6 inhibitors and/or chemotherapy, they may gradually develop drug resistance and result in treatment failure. Novel therapeutic options are urgently needed for patients after drug resistance. As an innovative therapy for drug-resistant patients with this subtype of breast cancer, AKT inhibitors offer new hope for them and their families.
お知らせ • Aug 08Laekna, Inc. to Report First Half, 2026 Results on Aug 25, 2026Laekna, Inc. announced that they will report first half, 2026 results on Aug 25, 2026
お知らせ • Jul 11Laekna, Inc. (SEHK:2105) commences an Equity Buyback Plan for 44,933,135 shares, representing 10% of its issued share capital, under the authorization approved on June 5, 2026.Laekna, Inc. (SEHK:2105) commences share repurchases on July 9, 2026, under the program mandated by the shareholders in the Annual General Meeting held on June 5, 2026. As per the mandate, the company is authorized to repurchase up to 44,933,135 units, representing 10% of its issued share capital. The purpose for the buyback is to enhance the net asset value per share and/or earnings per share. The repurchases will be made out of the funds legally available for such purpose in accordance with trust deed and applicable laws of, and regulations in Hong Kong. The shares repurchased will be cancelled. The authority shall expire at the earliest of the next Annual General Meeting, the date on which the next Annual General Meeting is required to be held or the date on which the authority is carried out to the full extent, unless varied or revoked in a General Meeting. As of May 14, 2026, the company had 449,331,350 shares in issue. On July 2, 2026, the company announces a Share Repurchase Program. Under the program, the company will repurchase up to HKD 56 million worth of its shares. The share share repurchase will be funded by the Company’s existing available cash resources.
お知らせ • May 15Laekna, Inc., Annual General Meeting, Jun 05, 2026Laekna, Inc., Annual General Meeting, Jun 05, 2026, at 09:00 China Standard Time. Location: 5f, 987 cailun road, pudong, shanghai, china, Hong Kong
お知らせ • Mar 06Laekna, Inc. to Report Fiscal Year 2025 Results on Mar 18, 2026Laekna, Inc. announced that they will report fiscal year 2025 results at 4:00 PM, China Standard Time on Mar 18, 2026
お知らせ • Jan 14Laekna, Inc. Announces That the U.S. Food and Drug Administration Has Accepted Its Investigational New Drug Application for LAE118The board of directors of Laekna, Inc. announced that the U.S. Food and Drug Administration has accepted its Investigational New Drug application for LAE118, a novel PI3K a pan-mutant selective inhibitor for the treatment of patients with PIK3CA-mutant solid tumors. The Company will work closely with the regulatory authorities to complete the application. Building on its proven track record in successfully developing and out-licensing LAE002 (afuresertib), the Company aims to bring this precision therapy to cancer patients who are in need of novel treatment options.
お知らせ • Jan 02Laekna, Inc. Commences Study Recruitment in Phase I Single Ascending Dose Study of LAE103The board of directors of Laekna, Inc. announced that the Group has commenced study recruitment in phase I single ascending dose study of LAE103, an internally discovered monoclonal antibody against ActRIIB, in Australia. As of the date of this announcement, first subject has been dosed. The SAD Study is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of LAE103, administered subcutaneously, in healthy overweight or obese participants. The Group targets to read out the topline data of this SAD study in the third quarter of 2026. The Group targets to bring this precision therapy to cardiovascular and metabolic diseases with high unmet medical needs, such as obesity, sarcopenia and heart failure.
お知らせ • Sep 18Laekna, Inc. has completed a Follow-on Equity Offering in the amount of HKD 586.8 million.Laekna, Inc. has completed a Follow-on Equity Offering in the amount of HKD 586.8 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 36,000,000 Price\Range: HKD 16.3 Discount Per Security: HKD 0.26 Transaction Features: Subsequent Direct Listing
お知らせ • Sep 11Laekna, Inc. has filed a Follow-on Equity Offering in the amount of HKD 586.8 million.Laekna, Inc. has filed a Follow-on Equity Offering in the amount of HKD 586.8 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 36,000,000 Price\Range: HKD 16.3 Discount Per Security: HKD 0.26 Transaction Features: Subsequent Direct Listing
お知らせ • Jul 29Laekna, Inc. to Report First Half, 2025 Results on Aug 13, 2025Laekna, Inc. announced that they will report first half, 2025 results on Aug 13, 2025
お知らせ • Jun 30Laekna, Inc. Submits Investigational New Drug Application to the U.S. Food and Drug AdministrationThe board of directors of Laekna, Inc. announced that the Group has submitted an Investigational New Drug application to the U.S. Food and Drug Administration for LAE103, an internally discovered monoclonal antibody against ActRIIB for the treatment of patients with sarcopenic obesity and muscle related disease. The Company will work closely with the regulatory authorities to complete the application and targets to bring this precision therapy to metabolic patients who are in need of novel treatment options. The Group plans to separately evaluate the efficacy and safety of monoclonal antibodies targeting at ActRIIA and ActRIIB in humans.
お知らせ • Jun 24Laekna Presents Clinical and Pre-clinical Studies Results of LAE102, LAE103 and LAE123Laekna announced that the results of: i) the phase I SAD study of LAE102 (an ActRIIA-selective antibody) for the treatment of obesity; and ii) the pre-clinical study of LAE102, LAE103 (an ActRIIB-selective antibody) and LAE123 (an ActRIIA/IIB dual antagonistic monoclonal antibody) as therapeutics for muscle growth and fat reduction were presented at the 85th scientific sessions of the American Diabetes Association (ADA). ADA is one of the global leading conferences dedicated to diabetes research, care, and innovation and has taken place in Chicago, USA, from June 20 to 23 this year. Professor Xuening LI, Zhongshan Hospital affiliated to Fudan University,Principal Investigator of the Phase I Clinical Trial of LAE102 in China. At the ADA Scientific Sessions, Laekna showcased LAE102, LAE102, LAE 103, and LAE123 - an innovative portfolio targeting the ActRII pathway - highlighting team's extensive expertise and leadership in this field. Highlights: A total of 40 participants were enrolled in Part A (IV) and 24 participants in Part B (SC). All participants completed the study as designed. The mean age was 29.0 years and 31.2 years, with the mean BMI 23.32 kg/m2 and 23.08 kg/m2 in Part A and Part B, respectively.
お知らせ • Jun 23Laekna, Inc. Announces Results of Phase I Sad Study of Lae102Laekna, Inc. announced that the results of (i) phase I SAD study of LAE102 (an ActRIIA-selective antibody) for the treatment of obesity; and (ii) the pre-clinical study of LAE102, LAE103 (an ActRIIB-selective antibody) and LAE123 (an ActRIIA/IIB dual antagonistic monoclonal antibody) as therapeutics for muscle growth and fat reduction were presented at the 85th scientific sessions of the American Diabetes Association (ADA). Presentations details are as follows: Poster No.1. Abstract Number: 2205-LB, Title: First-in-Human Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LAE102 in Healthy volunteers, Time: Sunday, June 22, 2025, 12:30 p.m.-13:30 p.m. CST, Location: Poster Hall (Hall F1) McCormick Place Convention Center, Chicago, Illinois, the USA. Highlights: A total of 40 participants were enrolled in Part A (IV) and 24 participants in Part B (SC). All participants completed the study as designed. The mean age was 29.0 years and 31.2 years, with the mean BMI 23.32 kg/m2 and 23.08 kg/m2 in Part A and Part B, respectively. Baseline demographic and clinical characteristics were generally balanced across the intravenous (IV) and subcutaneous (SC) cohorts of the study. Overall, LAE102 was well tolerated following a single IV or SC dose. No serious adverse events or treatment emergent adverse events (TEAEs) leading to discontinuation of treatment were reported. The majority of the TEAEs were mild laboratory test abnormalities, which were asymptomatic and did not require medical intervention. There was no reported case of diarrhea. Activin A was significantly increased in 24 hours following a single intravenous or subcutaneous dose of LAE102. The duration of Activin A elevation was dose-dependent. The high-dose groups (8 mg/kg IV group, 16 mg/kg IV group, and 8 mg/kg SC group) maintained 2-to-3-fold increases above the baseline level through 28 days post-administration, indicating prolonged pathway blocking. In addition, they also inhibit activin E and GDF3, which promote lipid accumulation of adipose tissue. In mouse models, LAE102 alone significantly induced muscle growth and reduced fat mass, while LAE103 had less effect. Notably, a synergistic effect on muscle increase and fat loss was observed when combining LAE102 with LAE103, achieving the maximal effect comparable to the ActRIIA-IIB dual-specific antibody LAE123. This positions LAE102 as a promising drug candidate for achieving quality weight control.
お知らせ • May 13Laekna, Inc., Annual General Meeting, Jun 03, 2025Laekna, Inc., Annual General Meeting, Jun 03, 2025, at 09:00 China Standard Time. Location: 5f, 987 cailun road, pudong, shanghai China
お知らせ • Mar 26Laekna, Inc. Commences Study Recruitment in Phase I Multiple Ascending Dose Study of Lae102 for the Treatment of ObityThe board of directors of Laekna, Inc. announced that the Group has commenced study recruitment in phase I multiple ascending dose study of LAE102 in China for the treatment of obesity. As of the date of this announcement, the first visit for the first subject has been completed. The MAD Study is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of LAE102, administered subcutaneously, in 60 overweight/obese subjects. The Group aims to bring this precision therapy to overweight and obese patients who are in need of novel treatment options for achieving quality weight control.
お知らせ • Mar 10Laekna, Inc. to Report Fiscal Year 2024 Results on Mar 24, 2025Laekna, Inc. announced that they will report fiscal year 2024 results on Mar 24, 2025
お知らせ • Jan 13Laekna, Inc. Announces Completion of A Successful Phase I Single Ascending Dose Study of Lae102 for the Treatment of ObesityThe board of directors of Laekna, Inc. announced that the Group has successfully completed the phase I single ascending dose study of LAE102 for the treatment of obesity. The SAD Study enrolled a total of 64 healthy subjects with an average BMI of 23.2+-2.2 kg/m2, including 5 intravenous cohorts and 3 subcutaneous cohorts. The positive outcomes of the SAD Study results have established a solid foundation for the coming phase I multiple ascending dose study in China as well as the phase I clinical study in collaboration with Eli Lilly & Company in the U.S. The SAD Study data of LAE102 analyzed to date demonstrated an encouraging safety and tolerability profile, with no serious adverse events and no discontinuations due to adverse events. All treatment emergent adverse events reported to date were very well tolerated, with the majority of them being reported as mild (grade 1) lab test abnormality without any clinical symptoms or signs. There is no reported case of diarrhea. Obvious target engagements and expected pharmacodynamic biomarker changes have been observed. Single doses of LAE102 resulted in significant and sustained increasing in activin A level, indicating a robust target engagement. The duration of target engagement correlated to the dose level. The detailed study results will be presented in a scientific conference as soon as possible. The positive SAD Study results support continuing the investigation of LAE102 for thetreatment of obesity. The Group plans to initiate the MAD Study in the first quarter of 2025 and to work closely with Lilly to commence the phase I clinical study in U.S. as soon as possible. The MAD Study is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of LAE102, administered subcutaneously, in 60 overweight/obese subjects. The Group aims to bring this precision therapy to overweight and obese patients who are in need of novel treatment options for achieving quality weight control.